Stifel analyst Adam Walsh noted that the US Patent Trial and Appeal Board, or PTAB, released a final written decision in the inter partes review case between Corcept Therapeutics (CORT) and Neptune Generics, ruling in a "clear win" for Corcept that Neptune has not shown by a preponderance of the evidence that claims 1-7 of U.S. Patent No. 8,921,348 related to Korlym are unpatentable. Walsh said he still thinks that the PTAB PGR decision in November on the '214 patent, the Federal trial against Teva (TEVA) and the emerging pipeline are the main drivers of Corcept shares this year. He keeps a Hold rating on Corcept Therapeutics shares, which closed 3.5% higher at $14.04.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here